$ACT Recent News Actavis continues pharmaceuticals

New Post Public Reply Private Reply Replies (1) Message Board

Jan 27, 2014 at 5:51 PM

$ACT Recent News

Actavis continues pharmaceuticals dominance 11:33 a.m. Jan. 16, 2014 - The Trading Deck
13 stocks set to outperform in 2014 from Sabrient's David Brown 7:21 p.m. Jan. 14, 2014 - blogs.marketwatch.com
Selling in growth-stock leaders continues 11:23 a.m. Oct. 31, 2013 - The Trading Deck
BlackBerry gains on Facebook talk; Apple red 3:00 p.m. Oct. 29, 2013 - Sue Chang
FDA recommends new limits on pain drugs 10:25 p.m. Oct. 24, 2013 - Thomas M. Burton
Large investors refuse to sell this market 11:05 a.m. Oct. 1, 2013 - The Trading Deck
A bull market not ready to be put to rest 11:14 a.m. Sept. 5, 2013 - The Trading Deck
10 popular health-care stocks among hedge funds 11:34 a.m. Sept. 4, 2013 - Insider Monkey
James Dinan's top stock picks 9:11 a.m. Aug. 21, 2013 - Insider Monkey
Major U.S. benchmarks take technically shaky turn 11:18 a.m. Aug. 15, 2013 - Michael Ashbaugh
Dow holds major support, Nasdaq presses new highs 9:39 a.m. July 29, 2013 - Michael Ashbaugh
Perrigo to buy biotech Elan in $8.6 billion deal 3:51 a.m. July 29, 2013 - Jonathan D. Rockoff
Actavis, Warner shares climb as investors anticipate pending merger 2:07 p.m. July 26, 2013 - Russ Britt
Actavis loss widens on impairment charge 6:58 a.m. July 25, 2013 - MarketWatch.com
Charting a slow-motion rally to record territory 11:06 a.m. July 23, 2013 - Michael Ashbaugh
Charting a slow-motion rally to record territory 10:50 a.m. July 23, 2013 - Michael Ashbaugh
Hedge fund conference picks: winners and losers 6:17 p.m. July 16, 2013 - William L. Watts
Supreme Court satisfies few with ruling on generic drug settlements 4:30 p.m. June 18, 2013 - Russ Britt
Supreme Court decision on generics hits Actavis, but few other drug firms 11:46 a.m. June 17, 2013 - Russ Britt
U.S. stock benchmarks rally from obvious support 9:51 a.m. June 10, 2013 - Michael Ashbaugh

Will Pfizer (PFE) Miss This Earnings Season? - Analyst Blog 4:50 p.m. Today - Zacks.com
Allergan Slips on Restasis Challenge - Analyst Blog 1:50 p.m. Jan. 23, 2014 - Zacks.com
Pharma Stocks Like Actavis Continue To Dominate At The Start Of 2014 6:40 a.m. Jan. 23, 2014 - Seeking Alpha
Teva to Acquire NuPathe - Analyst Blog 4:58 p.m. Jan. 22, 2014 - Zacks.com
Narrower-than-Expected Loss at Ironwood, Shares Up - Analyst Blog 3:31 p.m. Jan. 22, 2014 - Zacks.com
Why Actavis (ACT) Has A Bright Short-Term Future? - Tale of the Tape 8:42 a.m. Jan. 22, 2014 - Zacks.com
More U.S. Companies Realize China Isn’t Worth the Trouble 4:27 a.m. Jan. 22, 2014 - InvestorPlace.com
Mallinckrodt Up on FDA Approval - Analyst Blog 12:10 p.m. Jan. 21, 2014 - Zacks.com
Will Cubist Pharma (CBST) Miss Earnings? - Analyst Blog 9:40 a.m. Jan. 21, 2014 - Zacks.com
Actavis Joins the Divestment Bandwagon - Analyst Blog 5:55 p.m. Jan. 20, 2014 - Zacks.com
Will Forest Labs (FRX) Beat Earnings Again? - Analyst Blog 11:10 a.m. Jan. 20, 2014 - Zacks.com
Actavis sells generic-pharma ops in seven European markets 2:57 a.m. Jan. 19, 2014 - Seeking Alpha
China Biotech In Review: Thermo Fisher Approved For Acquisition Of Life Technologies 2:07 a.m. Jan. 19, 2014 - Seeking Alpha
Actavis Announces Agreement with Aurobindo Pharma to Divest Commercial Operations in Seven Western European Countries 3:33 p.m. Jan. 18, 2014 - benzinga.com
Several IBD 50 Medical Companies Seen Posting Strong Q4 Profit Gains 5:16 p.m. Jan. 17, 2014 - Investors Business Daily
Actavis Leads the Way 10:21 a.m. Jan. 17, 2014 - TheStreet.com
BioLineRx Progresses with BL-8040 - Analyst Blog 5:10 p.m. Jan. 16, 2014 - Zacks.com
Actavis to exit China, Bisaro says too much trouble for too little profit 11:03 a.m. Jan. 16, 2014 - Seeking Alpha
Drug Buyouts On The Rise -- But Buyers Changing 5:42 p.m. Jan. 15, 2014 - Investors Business Daily
Actavis Discusses Preliminary Q4 Results - Analyst Blog 4:53 p.m. Jan. 15, 2014 - Zacks.com

Actavis Announces Agreement with Zhejiang Chiral Medicine Chemicals Co., Ltd to Divest Actavis Foshan, China 4:05 p.m. Jan. 24, 2014 - PR Newswire - PRF
Actavis Comments on Notification to Allergan, Inc. of Submission of Application for Restasis® 12:41 p.m. Jan. 22, 2014 - PR Newswire - PRF
Actavis Announces Agreement with Aurobindo Pharma Limited to Divest Commercial Operations in Seven Western European Countries 9:45 p.m. Jan. 17, 2014 - PR Newswire - PRF
Actavis Confirms Court Upholds Lo Loestrin® Fe Patent 5:42 p.m. Jan. 17, 2014 - PR Newswire - PRF
Pharma Industry Technical Data: Zoetis, Avanir Pharma, Actavis, and Salix Pharma 7:30 a.m. Jan. 16, 2014 - PR Newswire - PRF
Actavis Announces Preliminary Financial Performance for FY 2013 8:00 a.m. Jan. 14, 2014 - PR Newswire - PRF
Actavis Appoints Industry Veterans to Lead U.S. Specialty Brands Business Units 7:30 a.m. Jan. 14, 2014 - PR Newswire - PRF
Upcoming Earnings Conference Calls, FDA Approvals, and Share Price Updates - Research Report on Actavis, ResMed, West Pharmaceutical, Sirona Dental Systems, and Theravance 8:00 a.m. Jan. 13, 2014 - PR Newswire - PRF
Actavis' Generic Version of Micardis® Receives FDA Approval 4:57 p.m. Jan. 8, 2014 - PR Newswire
Actavis to Host 2014 Investor Meeting January 31 in New York 4:25 p.m. Jan. 6, 2014 - PR Newswire
Conference Calls, Regulatory Filings, and Member Enrollment - Research Report on UnitedHealth Group, AbbVie, Lilly, Actavis, and Humana 8:00 a.m. Jan. 6, 2014 - PR Newswire
Actavis Confirms Generic NuvaRing® Patent Challenge 9:00 a.m. Dec. 24, 2013 - PR Newswire
Actavis Receives Complete Response Letter from FDA For Progestin-Only Patch 8:00 a.m. Dec. 24, 2013 - PR Newswire
Commercial Agreements, Stock Price Updates, Regulatory Approvals, Patent Litigation Settlements, and New Health Plan Strategies - Research Report on Biogen, Express Scripts, GSK, Actavis, and Aetna 8:00 a.m. Dec. 23, 2013 - PR Newswire
Actavis to Present at the 32nd Annual J.P. Morgan Healthcare Conference 9:25 a.m. Dec. 20, 2013 - PR Newswire
Vensun Pharmaceuticals, Inc. Completes Series B Financing 9:35 a.m. Dec. 19, 2013 - BusinessWire
Zimmer Holdings Names Paul Bisaro to Board of Directors 5:00 p.m. Dec. 16, 2013 - PR Newswire
Technical Research on Equities: Zoetis, Actavis, Avanir Pharma, and Salix Pharma 8:00 a.m. Dec. 16, 2013 - PR Newswire
Clinical Trial Results, Share Repurchase Transactions, Stock Price Updates, Appointments, and Investments - Research Report on AbbVie, Express Scripts, Actavis, Bristol-Myers Squibb, and GSK 8:00 a.m. Dec. 13, 2013 - PR Newswire
Actavis Announces Tentative Agreement Related to Asacol® HD Patent Challenge Litigation 8:00 a.m. Dec. 11, 2013 - PR Newswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Hartford Students Get Boost from Hygiene Initiatives

Beyond Backpacks: Essential Hygiene for Hartford Kids When September rolls around, it’s not just about those shiny new backpacks and unopened notebooks. In good ol’ Hartford, some students find themselves in need of basics that get overlooked—a stick of deodorant, a bar of soap, maybe some period products. Skimp on these, and all of a sudden, showing up for school...

Freeport-McMoRan Hit with Legal Probe: What's Next?

Investigating the Movers and Shakers at Freeport When legal hawks like Kahn Swick & Foti, LLC sink their teeth into something, you can bet it's not just to nibble. These folks have jumped headfirst into probing Freeport-McMoRan Inc. (NYSE:FCX), ready to dismantle any smoke screens that might have been thrown up after the unfortunate Grasberg Block Cave mine incident. The...

GoDaddy Faces Class Action: Investor Stakes High

GoDaddy's Legal Turbulence: What's at Stake? Sometimes riding the stock wave can hit unexpected snags, and that's what's up with GoDaddy right now. They're stuck in the middle of a securities deception storm that's sending shivers down the spine of many an investor. The Class Action Lawsuit's Core Here's what you need to know: GoDaddy, with its ticker NYSE:GDDY, is...

BellRing Brands Faces Legal Probe; Fiduciary Duties Questioned

What's Stirring at BellRing Brands? Hey, no time like the present to dive headfirst into this mess BellRing's found itself in. On the heels of a lackluster sales forecast, just announced about a year ago, Kahn Swick & Foti's got their magnifying glasses out, searching for any shady dealings by those running the show at BellRing Brands, LLC. Why Is BellRing in the Hot...

New Concierge Pediatric Care at Weill Cornell Launches

A New Way Forward in Pediatric Care When a couple of seasoned pediatricians decide it's time for something fresh, eyes and ears perk up. Enter Dr. Paul W. Chung and Dr. Jane E. Rosini, diving headfirst into a revolutionary pediatric concierge program courtesy of Concierge Choice Physicians (CCP). We're talking a substantial shake-up at Weill Cornell Medicine, aiming to...

AARP New York Promotes Affordable 'Staycation' Experiences

Exploring New York Without Breaking the Bank Tough times call for creative solutions, and AARP New York is on the ball. With travel costs soaring and many older New Yorkers scrimping to make ends meet, the 'Staycation' campaign steps in with an offer too good to pass up: uncovering the gems of New York right under our noses without shelling out hefty sums. The plan? Turn...

Acepodia's ACE723 Clears FDA Hurdle for Hepatocellular Push

Unexpected Developments from Acepodia Folks keeping a keen eye on the biotech scene might just raise an eyebrow at Acepodia's latest move. The FDA has given their nod to ACE723, an ambitious dual-payload antibody-drug conjugate (ADC) designed to wrangle with those stubborn cases of unresectable or metastatic hepatocellular carcinoma (HCC). This isn't just another day in...

Kansas City's Haunts Condense Season to 13 Nights

A Scary Short Season Takes Center Stage Hold onto your ghost hats, folks! The Kansas City haunt legends are shaking things up with a shorter scare season. This October, the infamous Edge of Hell and The Beast attractions are packing in the frights over just 13 nights, shifting their schedule due to rising September temperatures. Now, ain't that something? For their 52nd...

Carles Puyol Joins Midea at IFA 2026, Celebrating Unity

Leadership, Innovation, and Soccer Collide in Berlin When you’ve got a Barcelona legend like Carles Puyol gracing an event, it's more than just fanfare. This time around, Puyol made waves at Midea's stand during IFA 2026 in Berlin, signaling a strategic power move for both Midea and FC Barcelona. We're talking about a scene where tech innovation meets world-class...

Delisting Gray Wolf Sparks Heated Hunter Nation Debate

Unraveling the Gray Wolf Controversy What are we looking at here—political maneuvering wrapped in a fur coat? Trump's executive order is making some calls I didn’t see coming. By pushing to delist the gray wolf from the Endangered Species Act (ESA), he's stirring up a mix of joy, outrage, and a boatload of debate about environmental ethics, conservation priorities,...